IGF-1 vs TB-500 (Thymosin Beta-4)
IGF-1 and TB-500 (Thymosin Beta-4) are studied in overlapping research areas, which is why they are frequently compared. This is a neutral side-by-side reference drawn from published preclinical literature and laboratory handling data.
How they actually differ
Comparing the two: IGF-1 is 70-residue single-chain protein (native igf-1), three disulfide bonds, while TB-500 (Thymosin Beta-4) is synthetic fragment of thymosin beta-4 — different molecular classes with different handling consequences; they call for different primary diluents (dilute acetic acid for initial dissolution versus bacteriostatic water (0.9% benzyl alcohol)); their leading degradation routes differ (misfolding and irreversible denaturation for IGF-1, methionine sulfoxide formation for TB-500 (Thymosin Beta-4)), so the storage precautions that matter are not the same; their practical working windows differ once reconstituted. The sections below set out each in full.
IGF-1 — origin
IGF-1 is the native insulin-like growth factor — a folded 70-amino-acid protein stabilised by three internal disulfide bonds. It is the downstream messenger produced after growth hormone acts, and it is handled as a protein rather than a short peptide. This is the native sequence, distinct from the long-acting LR3 analogue.
TB-500 (Thymosin Beta-4) — origin
TB-500 corresponds to the active region of Thymosin Beta-4, a 43-residue actin-sequestering protein present in virtually every mammalian cell type and abundant in wound fluid and platelets. Research interest followed the observation that the protein's activity in tissue-organisation models is largely retained by a short fragment of it.
IGF-1 research themes
Studied as the native ligand for the IGF-1 receptor and its downstream proliferation and survival pathways.
Examined in muscle research models for its role in satellite-cell behaviour and anabolic signalling.
Compared with IGF-1 LR3, whose reduced binding-protein affinity gives a longer active window — a contrast studied directly in the literature.
TB-500 (Thymosin Beta-4) research themes
The defining studied mechanism: binding G-actin and influencing the polymerisation equilibrium that governs cell motility.
Investigated in models where directed cell movement into a tissue defect is the measured endpoint.
Two of the better-populated preclinical literatures for the parent protein.
Studied for effects on inflammatory signalling in tissue-injury models.
IGF-1 handling
- Dissolve first in dilute acetic acid, then dilute into the working buffer — never expect plain water to take it up fully.
- Use a carrier protein and low-bind labware to prevent adsorptive loss.
- Aliquot for single use; do not re-freeze reconstituted protein.
TB-500 (Thymosin Beta-4) handling
- Minimise headspace exposure — each opening introduces oxygen that drives methionine oxidation.
- Keep reconstituted vials out of direct light, including bench lighting over long sessions.
- Introduce diluent against the vial wall; the cake is light and can be dispersed by a direct stream before it dissolves.
Both third-party tested
Every Popular Peptides batch of IGF-1 and TB-500 (Thymosin Beta-4) is independently tested by HPLC and LC-MS with a published Certificate of Analysis. Enter a lot number to pull the COA for a specific vial.
IGF-1 reference
Related comparisons
IGF-1 and TB-500 (Thymosin Beta-4) are supplied strictly as research chemicals for in-vitro laboratory and research use only. They are not intended for human or animal consumption, diagnostic, or therapeutic use. This comparison summarizes published preclinical literature and laboratory handling data; it is not medical advice, not a claim of efficacy, and not usage guidance.